On May 5, 2025, Chardan Capital, through analyst Daniil Gataulin, reaffirmed their 'Buy' rating on Tourmaline Bio (TRML, Financial). The investment firm continues to see potential in Tourmaline Bio, maintaining their price target at $70.00 USD.
The consistency in rating from 'Buy' and an unaltered price target suggest Chardan Capital's sustained confidence in the future performance of Tourmaline Bio (TRML, Financial). This steady outlook could be indicative of the company's stable prospects in the market.
With Chardan Capital's maintained rating and price target, investors in Tourmaline Bio (TRML, Financial) may find reassurance in the affirmation of the company's current valuation and growth potential, as suggested by the analyst's unchanged forecast.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $53.56 with a high estimate of $65.00 and a low estimate of $35.00. The average target implies an upside of 228.56% from the current price of $16.30. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
